Retrospective, real-world results showed that patients treated with oral decitabine and cedazuridine and standard parenteral hypomethylating agents (HMAs) for myelodysplastic syndrome (MDS) demonstrated similar levels of comorbidities and disease burden to patients treated with intravenous (IV)/subcutaneous (SC) HMAs.
Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.
The guidelines include 46 evidence- and consensus-based recommendations about the use of methotrexate for inflammatory skin disease in pediatric patients developed by a committee of 23 experts.
Atezolizumab plus a modified docetaxel, cisplatin and 5-fluorouracilregimen is a safe and effective first-line treatment for locally advanced squamous cell anal carcinoma, according to research presented at 2022 ASCO Annual Meeting.Anal carcinomas make up 2.7% of gastrointestinal cancers, which has increased over time, according to the study's authors.
Certain cancers, particularly pancreatic malignancies, may increase the risk of developing new-onset type 2 diabetes, meaning that oncologists should consider screening.